{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bradykinin", "query": { "intervention": "Bradykinin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bradykinin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T13:31:22.933Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01413542", "title": "Pharmacogenetics of Ace Inhibitor-Associated Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension", "Diabetes Type 2" ], "interventions": [ { "name": "Sitagliptin (DPP4 inhibitor)", "type": "DRUG" }, { "name": "Substance P,", "type": "DRUG" }, { "name": "bradykinin", "type": "DRUG" }, { "name": "enalaprilat (ACE inhibitor)", "type": "DRUG" }, { "name": "Glucagon-like peptide 1", "type": "DRUG" }, { "name": "brain natriuretic peptide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2011-11", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413542" }, { "nct_id": "NCT05396105", "title": "Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hereditary Angioedema", "Hereditary Angioedema Type I", "Hereditary Angioedema Type II", "Hereditary Angioedema Types I and II", "Hereditary Angioedema Attack", "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency", "Hereditary Angioedema - Type 1", "Hereditary Angioedema - Type 2", "Hereditary Angioedema - Type 3", "C1 Esterase Inhibitor [C1-INH] Deficiency", "C1 Esterase Inhibitor Deficiency", "C1 Esterase Inhibitor, Deficiency of", "C1 Inhibitor Deficiency", "Hereditary Angioedema Type III", "Hereditary Angioedema (HAE)", "Hereditary Angioedema Type I and II", "HAE With Normal C1 Esterase Inhibitor" ], "interventions": [ { "name": "deucrictibant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 150, "start_date": "2022-12-28", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05396105" }, { "nct_id": "NCT00001461", "title": "Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atherosclerosis", "Coronary Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 209, "start_date": "1995-03", "completion_date": "2001-04", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001461" }, { "nct_id": "NCT00868855", "title": "Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Bradykinin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2003-12", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00868855" }, { "nct_id": "NCT01595516", "title": "Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Prehypertension", "Hypertension" ], "interventions": [ { "name": "Nebivolol", "type": "DRUG" }, { "name": "Metoprolol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bradykinin", "type": "OTHER" }, { "name": "Saline", "type": "OTHER" }, { "name": "Vitamin C", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Colorado, Boulder", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "45 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2012-02", "completion_date": "2017-10", "has_results": true, "last_update_posted_date": "2019-06-25", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 1, "location_summary": "Boulder, Colorado", "locations": [ { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01595516" }, { "nct_id": "NCT07046806", "title": "Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hereditary Angioedema (HAE)", "Angioedema", "Bradykinin-mediated Angioedema", "C1 Inhibitor Deficiency" ], "interventions": [ { "name": "Deucrictibant XR tablet", "type": "DRUG" }, { "name": "Placebo comparator to XR tablet", "type": "DRUG" }, { "name": "Deucrictibant 20 mg capsule", "type": "DRUG" }, { "name": "Placebo comparator to 20 mg capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institute for Asthma and Allergy", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2025-03-10", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 1, "location_summary": "Wheaton, Maryland", "locations": [ { "city": "Wheaton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07046806" }, { "nct_id": "NCT06343779", "title": "Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema", "Hereditary Angioedema Type I", "Hereditary Angioedema Type II", "Hereditary Angioedema Types I and II", "Hereditary Angioedema Attack", "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency", "Hereditary Angioedema - Type 1", "Hereditary Angioedema - Type 2", "C1 Esterase Inhibitor [C1-INH] Deficiency", "C1 Esterase Inhibitor Deficiency", "C1 Esterase Inhibitor, Deficiency of", "C1 Inhibitor Deficiency", "Hereditary Angioedema - Type 3", "Hereditary Angioedema Type III" ], "interventions": [ { "name": "Deucrictibant, Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 134, "start_date": "2024-02-26", "completion_date": "2025-10-17", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06343779" }, { "nct_id": "NCT06679881", "title": "Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema (HAE)" ], "interventions": [ { "name": "Deucrictibant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 170, "start_date": "2025-02-01", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679881" }, { "nct_id": "NCT00083356", "title": "Bradykinin Receptors and Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tooth, Impacted" ], "interventions": [ { "name": "Wisdom tooth extraction", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Institute of Nursing Research (NINR)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 90, "start_date": "2004-05", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083356" }, { "nct_id": "NCT05047185", "title": "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hereditary Angioedema", "Hereditary Angioedema Type I", "Hereditary Angioedema Type II", "Hereditary Angioedema Types I and II", "Hereditary Angioedema Attack", "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency", "Hereditary Angioedema - Type 1", "Hereditary Angioedema - Type 2", "C1 Esterase Inhibitor Deficiency", "C1 Inhibitor Deficiency" ], "interventions": [ { "name": "Deucrictibant low dose", "type": "DRUG" }, { "name": "Deucrictibant high dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharvaris Netherlands B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 34, "start_date": "2022-04-19", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-02T13:31:22.933Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047185" } ] }